{"entity":{"id":"hb-200","kind":"drug","name":"HB-200","aka":["HB-201","HB-202","Eseba-vec"],"tldr":"HB-200 is a vaccine built from two harmless engineered viruses that teach the immune system to attack the HPV16 proteins inside cervical and throat cancers. It has been tested with pembrolizumab in HPV16-positive head and neck cancer.","summary":"HB-200 is Hookipa Pharma's therapeutic vaccine for HPV16-positive cancers, made of two arenavirus vectors, HB-201 (based on lymphocytic choriomeningitis virus) and HB-202 (based on Pichinde virus), that express the same HPV16 E6/E7 fusion antigen. Alternating the two vectors avoids immunity against the vector itself and produced some of the largest antigen-specific T-cell expansions reported for a cancer vaccine.\n\nIt was given intravenously with pembrolizumab in phase 1/2 trials in recurrent or metastatic HPV16-positive head and neck squamous cell carcinoma, with response rates in the first-line setting above those expected from pembrolizumab alone. It is named on the recurrent or metastatic head and neck cancer page among the newer immunotherapy approaches for HPV-positive disease.","status":"phase-2","asOf":"2026-09-17","links":[],"tags":["subtype-drugs-wave"],"related":["pembrolizumab"],"cancers":["recurrent-metastatic-hnscc"],"sections":[],"technologies":["hpv-vaccine"],"targets":[],"drugs":[],"companies":["hookipa-pharma"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"code":"HB-200","modality":"Arenavirus-vector therapeutic vaccine (HPV16 E6/E7)","mechanism":"Two replicating arenavirus vectors (lymphocytic choriomeningitis and Pichinde virus) each carrying a non-oncogenic HPV16 E6/E7 fusion protein, given alternately to raise very high frequencies of E6- and E7-specific killer T cells against HPV16-driven tumours.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/hb-200/","neighbours":{"drug":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"cancer":[{"id":"recurrent-metastatic-hnscc","kind":"cancer","name":"Recurrent or metastatic head and neck squamous cell carcinoma","route":"/cancers/recurrent-metastatic-hnscc/"}],"technology":[{"id":"hpv-vaccine","kind":"technology","name":"HPV & HBV vaccination","route":"/technologies/hpv-vaccine/"}],"company":[{"id":"hookipa-pharma","kind":"company","name":"Hookipa Pharma","route":"/companies/hookipa-pharma/"}]}}